IMMUNITYBIO, INC. Operating Expenses
IMMUNITYBIO, INC. (IBRX) reported Operating Expenses of $358.93 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2025-03-03
- IMMUNITYBIO, INC. operating expenses for the quarter ending 2024-12-31 was $76.95M, a 10.03% decline year-over-year.
- IMMUNITYBIO, INC. operating expenses for the quarter ending 2024-09-30 was $86.36M, a 7.66% increase year-over-year.
- IMMUNITYBIO, INC. operating expenses for the quarter ending 2024-06-30 was $100.38M, a 17.84% increase year-over-year.
- IMMUNITYBIO, INC. operating expenses for the quarter ending 2024-03-31 was $95.24M, a 14.92% decline year-over-year.
- IMMUNITYBIO, INC. operating expenses for fiscal 2024 was $358.93M, a 1.09% decline from fiscal 2023.
- IMMUNITYBIO, INC. operating expenses for fiscal 2023 was $362.87M, a 3.22% increase from fiscal 2022.
- IMMUNITYBIO, INC. operating expenses for fiscal 2022 was $351.54M, a 6.14% increase from fiscal 2021.
- IMMUNITYBIO, INC. operating expenses for fiscal 2021 was $331.21M, a 49.54% increase from fiscal 2020.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $76.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $163.31M derived: sum of 2 quarters · filed 2025-03-03 | $263.69M derived: sum of 3 quarters · filed 2025-03-03 | $358.93M 10-K · filed 2025-03-03 | ||||
| 2024-09-30 | $86.36M 10-Q · filed 2024-11-12 | $186.74M derived: sum of 2 quarters · filed 2024-11-12 | $281.98M 10-Q · filed 2024-11-12 | $367.50M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2024-06-30 | $100.38M 10-Q · filed 2024-08-12 | $195.62M 10-Q · filed 2024-08-12 | $281.14M derived: sum of 3 quarters · filed 2025-03-03 | $361.36M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2024-03-31 | $95.24M 10-Q · filed 2024-05-09 | $180.76M derived: sum of 2 quarters · filed 2025-03-03 | $260.98M derived: sum of 3 quarters · filed 2025-03-03 | $346.17M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-12-31 | $85.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $165.75M derived: sum of 2 quarters · filed 2025-03-03 | $250.93M derived: sum of 3 quarters · filed 2025-03-03 | $362.87M 10-K · filed 2025-03-03 | ||||
| 2023-09-30 | $80.22M 10-Q · filed 2024-11-12 | $165.40M derived: sum of 2 quarters · filed 2024-11-12 | $277.34M 10-Q · filed 2024-11-12 | $362.32M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | $85.19M 10-Q · filed 2024-08-12 | $197.13M 10-Q · filed 2024-08-12 | $282.10M derived: sum of 3 quarters · filed 2025-03-03 | $373.02M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $111.94M 10-Q · filed 2024-05-09 | $196.91M derived: sum of 2 quarters · filed 2025-03-03 | $287.83M derived: sum of 3 quarters · filed 2025-03-03 | $367.49M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $84.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $175.90M derived: sum of 2 quarters · filed 2025-03-03 | $255.55M derived: sum of 3 quarters · filed 2025-03-03 | $351.54M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $90.92M 10-Q · filed 2023-11-09 | $170.58M derived: sum of 2 quarters · filed 2023-11-09 | $266.56M 10-Q · filed 2023-11-09 | $346.23M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | $79.66M 10-Q · filed 2023-08-08 | $175.64M 10-Q · filed 2023-08-08 | $255.31M derived: sum of 3 quarters · filed 2024-03-19 | $334.21M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | $95.99M 10-Q · filed 2023-05-11 | $175.65M derived: sum of 2 quarters · filed 2024-03-19 | $254.55M derived: sum of 3 quarters · filed 2024-03-19 | $340.80M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | $79.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $158.57M derived: sum of 2 quarters · filed 2024-03-19 | $244.81M derived: sum of 3 quarters · filed 2024-03-19 | $331.21M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | $78.90M 10-Q · filed 2022-11-09 | $165.15M derived: sum of 2 quarters · filed 2022-11-09 | $251.55M 10-Q · filed 2022-11-09 | $282.46M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $86.25M 10-Q · filed 2022-08-08 | $172.65M 10-Q · filed 2022-08-08 | $203.56M derived: sum of 3 quarters · filed 2022-08-08 | $269.58M derived: sum of 4 quarters · filed 2022-08-08 | ||||
| 2021-03-31 | $86.40M 10-Q · filed 2022-05-10 | $117.31M derived: sum of 2 quarters · filed 2022-05-10 | $183.34M derived: sum of 3 quarters · filed 2022-05-10 | $234.69M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $30.91M 10-K · filed 2021-03-04 | $96.94M derived: sum of 2 quarters · filed 2021-11-12 | $148.29M derived: sum of 3 quarters · filed 2021-11-12 | $221.49M 10-K · filed 2023-03-01 | $91.74M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $66.03M 10-Q · filed 2021-11-12 | $22.00M 10-Q · filed 2020-11-09 | $117.38M derived: sum of 2 quarters · filed 2021-11-12 | $154.25M 10-Q · filed 2021-11-12 | $60.83M 10-Q · filed 2020-11-09 | $170.37M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $51.35M 10-Q · filed 2021-08-12 | $20.23M 10-Q · filed 2020-08-07 | $88.22M 10-Q · filed 2021-08-12 | $38.84M 10-Q · filed 2020-08-07 | $104.34M derived: sum of 3 quarters · filed 2021-08-12 | $120.42M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $36.87M 10-Q · filed 2021-05-14 | $18.61M 10-Q · filed 2020-05-11 | $52.99M derived: sum of 2 quarters · filed 2021-05-14 | $69.06M derived: sum of 3 quarters · filed 2021-05-14 | $86.38M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2019-12-31 | $16.12M 10-K · filed 2021-03-04 | $32.20M derived: sum of 2 quarters · filed 2021-03-04 | $49.51M derived: sum of 3 quarters · filed 2021-03-04 | $158.45M 10-K · filed 2022-03-01 | $67.85M 10-K · filed 2020-03-25 | |||
| 2019-09-30 | $16.08M 10-K · filed 2021-03-04 | $33.39M derived: sum of 2 quarters · filed 2021-03-04 | $51.73M 10-Q · filed 2020-11-09 | $69.46M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | $17.31M 10-K · filed 2021-03-04 | $35.65M 10-Q · filed 2020-08-07 | $53.38M derived: sum of 3 quarters · filed 2021-03-04 | $77.52M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | $18.34M 10-K · filed 2021-03-04 | $36.07M derived: sum of 2 quarters · filed 2021-03-04 | $60.20M derived: sum of 3 quarters · filed 2021-03-04 | $88.49M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2018-12-31 | $17.73M 10-K · filed 2020-03-25 | $41.87M derived: sum of 2 quarters · filed 2020-03-25 | $70.15M derived: sum of 3 quarters · filed 2020-03-25 | $98.44M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | $24.14M 10-K · filed 2020-03-25 | $52.42M derived: sum of 2 quarters · filed 2020-03-25 | $80.71M 10-Q · filed 2019-11-05 | $106.12M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-06-30 | $28.28M 10-K · filed 2020-03-25 | $56.57M 10-Q · filed 2019-08-06 | $81.98M derived: sum of 3 quarters · filed 2020-03-25 | $106.43M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-03-31 | $28.29M 10-K · filed 2020-03-25 | $53.70M derived: sum of 2 quarters · filed 2020-03-25 | $78.14M derived: sum of 3 quarters · filed 2020-03-25 | $101.98M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2017-12-31 | $25.41M 10-K · filed 2019-03-13 | $49.86M derived: sum of 2 quarters · filed 2019-03-13 | $73.69M derived: sum of 3 quarters · filed 2019-03-13 | $99.17M 10-K · filed 2020-03-25 | ||||
| 2017-09-30 | $24.45M 10-K · filed 2019-03-13 | $48.28M derived: sum of 2 quarters · filed 2019-03-13 | $73.76M 10-Q · filed 2018-11-07 | $98.92M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-06-30 | $23.83M 10-K · filed 2019-03-13 | $49.31M 10-Q · filed 2018-08-06 | $74.47M derived: sum of 3 quarters · filed 2019-03-13 | $107.25M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-03-31 | $25.48M 10-K · filed 2019-03-13 | $50.63M derived: sum of 2 quarters · filed 2019-03-13 | $83.42M derived: sum of 3 quarters · filed 2019-03-13 | $118.40M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2016-12-31 | $25.16M 10-K · filed 2018-03-12 | $57.94M derived: sum of 2 quarters · filed 2018-03-12 | $92.92M derived: sum of 3 quarters · filed 2018-03-12 | $124.54M 10-K · filed 2019-03-13 | ||||
| 2016-09-30 | $32.79M 10-K · filed 2018-03-12 | $67.76M derived: sum of 2 quarters · filed 2018-03-12 | $99.39M 10-Q · filed 2017-11-07 | $129.32M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-06-30 | $34.98M 10-K · filed 2018-03-12 | $66.60M 10-Q · filed 2017-08-07 | $96.54M derived: sum of 3 quarters · filed 2018-03-12 | $143.00M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | $31.62M 10-K · filed 2018-03-12 | $31.59M 10-Q · filed 2016-05-16 | $61.56M derived: sum of 2 quarters · filed 2018-03-12 | $108.03M derived: sum of 3 quarters · filed 2018-03-12 | $238.51M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2015-12-31 | $29.94M 10-K · filed 2017-03-15 | $76.41M derived: sum of 2 quarters · filed 2017-03-15 | $206.89M derived: sum of 3 quarters · filed 2017-03-15 | $239.11M 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | $46.47M 10-K · filed 2017-03-15 | $42.80M 10-Q · filed 2015-11-12 | $176.95M derived: sum of 2 quarters · filed 2017-03-15 | $209.17M 10-Q · filed 2016-11-10 | $159.18M 10-Q · filed 2015-11-12 | $211.90M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-06-30 | $130.49M 10-K · filed 2017-03-15 | $84.17M 10-Q · filed 2015-09-10 | $162.71M 10-Q · filed 2016-08-15 | $116.37M 10-Q · filed 2015-09-10 | $165.44M derived: sum of 3 quarters · filed 2017-03-15 | $166.49M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-03-31 | $32.22M 10-K · filed 2017-03-15 | $34.95M derived: sum of 2 quarters · filed 2017-03-15 | $36.00M derived: sum of 3 quarters · filed 2017-03-15 | $37.33M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2014-12-31 | $2.73M 10-K · filed 2016-03-30 | $3.78M derived: sum of 2 quarters · filed 2016-03-30 | $5.10M derived: sum of 3 quarters · filed 2016-03-30 | $6.22M 10-K · filed 2017-03-15 | ||||
| 2014-09-30 | $1.05M 10-K · filed 2016-03-30 | $1.03M 10-Q · filed 2015-11-12 | $2.37M derived: sum of 2 quarters · filed 2016-03-30 | $3.51M 10-Q · filed 2015-11-12 | ||||
| 2014-06-30 | $1.32M 10-K · filed 2016-03-30 | $1.29M 10-Q · filed 2015-09-10 | $2.48M 10-Q · filed 2015-09-10 | |||||
| 2014-03-31 | $1.11M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |